NetworkNewsBreaks – Vivos Therapeutics Inc. Develops Potential, Nonsurgical Solution for Obstructive Sleep Apnea

June 19, 2020 12:52:18

Vivos Therapeutics, an emerging global leader in the treatment of obstructive sleep apnea (“OSA”), has developed a groundbreaking remedy that holds the potential to be a possible solution for the life-threatening condition. A recent article further discussing the company reads, “This innovative medical device technology company has created and patented a novel system to combat OSA caused by deficiencies and other tissue anomalies in craniofacial anatomy development — the root cause behind 98% of OSA cases. The Vivos System requires no surgery but is a multidisciplinary treatment protocol that consists of comfortable and customized oral devices.  Over the typical 18-to-24-month course of treatment, we believe the patient’s upper airway is remodeled and enhanced, thereby reducing the tissue obstructions that gave rise to the OSA. Thus, Vivos technology represents the first true hope of an effective and lasting nonsurgical OSA solution that, in most cases, doesn’t require a lifetime of treatment intervention.  For the first time, the salutation ‘good night’ will truly mean a good night for these sufferers.”

To view the full article, visit http://nnw.fm/J8y1Y

About Vivos Therapeutics Inc.

Vivos Therapeutics is an emerging global leader in the treatment of obstructive sleep apnea (“OSA”), a debilitating condition affecting nearly 1 billion people worldwide. Headquartered in Denver, Colorado, the company utilizes proprietary, groundbreaking technology; a proven, go-to-market strategy; and a powerful executive team dedicated to changing the face of health care by helping people of all ages properly breathe and sleep. At the core of Vivos’ mission to eradicate OSA is the Vivos System(R), a revolutionary clinical breakthrough in the treatment of sleep apnea caused by craniofacial anatomy development. The Vivos System multidisciplinary treatment protocol involves collaboration between physicians, specially trained dentists who have completed advanced training in craniofacial sleep medicine, and other ancillary health-care providers. In support of its growth strategy, Vivos has established FDA-approved and registered manufacturing facilities in the United States, Canada and Asia. For more information, visit the company’s website at www.VivosLife.com.

NOTE TO INVESTORS: The latest news and updates relating to Vivos Therapeutics are available in the company’s newsroom at http://nnw.fm/VVOS

About NetworkNewsWire

NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
[email protected]

NetworkNewsWire is part of the InvestorBrandNetwork.